To improve the health, quality of life and well-being of people through the development, manufacture and supply of the highest quality Liquid Medicine.
Our core values
Quality – We are committed to the pursuit of excellence in everything we do. All of our medicines – both licensed and ‘Specials’ are produced to the highest standards of good manufacturing practice (GMP).
Integrity – We have an open and ethical approach to our business practices. Published price lists are available for both licensed and “Special” medicines. We believe that transparency is key to building the trust of our stakeholders.
Innovation – We listen to our customers and respond to their needs through a continual programme of new product development of both licensed and ‘Specials’ liquid medicines. We support education through an innovative range of resources for healthcare professionals and patients.
Responsibility – We take responsibility to our stakeholders very seriously and put this commitment at the core of everything we do. For example we offer a 24 hour help line for healthcare professionals and respond to our customers quickly and efficiently.
- More than 40 years dedicated experience of liquid medicines
- Over 140 liquid medicines manufactured and supplied
- Based in Leeds, West Yorkshire, UK with 220 employees
- Part of Perrigo Company plc since 2013
- 4 million bottles of liquid medicines manufactured in 2015
- Awarded “Investors in People” and “Positive about Disabled”
Certificate Number 9256
Rosemont has been accredited for ISO 14001, which is the international standard for the environmental management of businesses. Rosemont is commited to the envirionment, and this accreditation process has evaluated what controls we have in place that affect the environment including: the use of natural resources, the handling and treatment of waste, and energy consumption.
Rosemont Pharmaceuticals Ltd have been awarded Investors in People which is the most successful framework for business improvement through people in the UK. At its heart, Investors in People is all about determining the right strategy, getting people on board, enhancing management practices and evaluating what’s working or needs further improvement.
Rosemont’s commitment to employing fair recruitment policies has been recognised with the award of an accreditation for the ‘Positive About Disabled'. This accreditation is only awarded to employers who clearly and consistently demonstrate a commitment to employing, retaining and developing the skills of individuals who possess a disability.
Rosemont have received full Halal approval from the Halal Food Authority (HFA) and the first 17 Rosemont liquid medicines have been awarded Halal certification.The liquid medicines receiving Halal approval do not contain alcohol or any ingredients derived from animals, making these products suitable for a wide range of patients across many different faiths
Rosemont Pharmaceuticals is proud to be a Bone Health Partner of the National Osteoporosis Society. By working together we want to make a positive impact on bone health in the UK.
The National Osteoporosis Society is the only UK-wide charity dedicated to improving the prevention, diagnosis and treatment of osteoporosis. The charity is working towards a brighter future for people with or at risk of fragile bones across the UK. This partnership plays a key role in supporting the aims of the charity – by working together we can put an end to preventable broken bones and help millions of people live without pain and disability.
By contributing to the Bone Health Partnership, a corporate membership programme, Rosemont Pharmaceuticals is working with the National Osteoporosis Society to increase understanding and awareness of osteoporosis and to prevent future fractures. Our contribution will enable the charity to provide information and support to those with the condition, help fund medical research into osteoporosis and allow for the development of new projects to improve treatment and diagnosis.
Rosemont Pharmaceuticals is pleased to support the National Osteoporosis Society.
Careers with Rosemont
Rosemont Pharmaceuticals Ltd is committed to recruiting people fairly and ethically. Click on Current Vacancies for more information.
Extensive Product range – liquid medicines for many therapeutic areas including cardiovascular, endocrine, central nervous system, gastro-intestinal and musculo-skeletal.
Exceptional Product quality – we produce all our medicines to the same exacting GMP standards, so whether they are licensed products or ‘Specials’ the quality will be exceptional.
Reliable delivery – delivery within 48 hours in over 99% of orders and within 24 hours available on request.
Outstanding Customer Service – dedicated and knowledgeable customer service team who provide expert support for our customers
Proven Shelf life – licensed and ‘Specials’ usually have a minimum 9 month shelf life with proven stability data available.
Award-winning Educational Resources – a wide range of resources designed to help healthcare professionals deliver the best possible care. Also, extensively researched patient information leaflets.
Healthcare professional advice service – 24 hour professional advice line available 365 days a year on 0113 244 1400
About Perrigo Company plc
Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter, prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients. The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies. For more information, visit http://www.perrigo.com/.
Community Support During 2015
The following patient groups and charities received financial support from Rosemont Pharmaceuticals Limited in 2015.
- The National Osteoporosis Society
- Christie Hospital, Manchester
- York Air Ambulance
- Leeds Hospital Trust
- The Stroke Association
- NARA - The Breathing Charity
- Friends of FOP
- The Lullaby Trust
The above information is correct at the time of writing (April 2016). Information will be updated on an annual.